Oracle Dispatch: What Do You Know About Q BioMed Inc

A recent article in Oracle Dispatch highlighted Q BioMed Inc. (OTCQB:QBIO).
Q BioMed Inc (OTCMKTS:QBIO) is a stock that’s been powering in an uptrend on the strength of the company’s recent announcements related to its initial deal with a research group to incubate and foster a new treatment for the wide open Glaucoma market in July, as well as its recent deal to add a potential multi-billion dollar cancer treatment asset to their stable of strategies.
Traders will note 7% added to share values of the name over the past month of action, but that move adds to its 100%-plus advance off the July lows around $1.50. Moreover, the company has witnessed a pop in interest, as transaction volume levels have recently pushed 260% over what the stock has registered over the longer term. It pays to take note of this fact with a float in play that’s very limited — barely over 5.1M shares. Traders should not overlook this combination, as a mechanically driven price squeeze can result from this type of mix of small float and ramping attention from traders.
The company focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. Its primary target indication is for a therapeutic eye-drop for the treatment of glaucoma in adults. The company’s lead candidate is MAN-01.
The big catalyst right now is about the closing of an exclusive license and option agreement for a FDA approved generic drug, Strontium Chloride. This licensed radiopharmaceutical agent is indicated for the treatment of pain associated with metastatic bone cancer. SR89 provides long lasting relief for patients suffering from bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. The drug is preferentially absorbed in bone metastases, it has been proven to provide a long-term effect resulting in non-narcotic cancer pain relief and enhanced quality of life. This palliative drug is expected to start generating revenue in less than 12 months.
Earning a current market cap value of $30.2M, QBIO has a decent store ($163k) of cash on the books, alongside total assets just under $170K, which compares with an appreciable load ($1.05M) of total accumulated debt. As noted above, this stock carries an extremely small float and is seeing both a sturdy uptrend and ramping volume. Currently being promoted with adds on yahoo QBIO is an exciting story in a high-growth market space. So there may be a ton of opportunity here, particularly if the squeeze action gets traction.
Connect with Q BioMed Inc. (OTCQB:QBIO) to receive an Investor Presentation.